News about "Novartis"

Novartis Reports Phase 3 Results for Pelacarsen in Cardiovascular Disease

Novartis reports phase 3 Lp(a)HORIZON topline results for pelacarsen, an investigational ASO targeting Lp(a) production in patients with cardiovascular disease (CVD).

Novartis | 05/09/2026 | By News Bureau

Novartis Remibrutinib Reduces Relapse Rates in Phase 3 RMS Trials

Novartis’ remibrutinib significantly reduces annualised relapse rates versus teriflunomide in phase 3 RMS trials, with a favorable safety profile and no liver safety signal.

Novartis | 02/09/2026 | By News Bureau

Novartis' Rhapsido Gains UK Approval as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria

Novartis has secured MHRA marketing authorisation for Rhapsido, the first oral Bruton’s tyrosine kinase inhibitor approved in the UK for adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamines.

Novartis | 10/08/2026 | By News Bureau

US FDA Expands Approval of Novartis' Pluvicto for Earlier Treatment of Advanced Prostate Cancer

The US FDA has approved Novartis' Pluvicto for use in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, expanding access to the radioligand therapy at an earlier stage of disease.

Novartis | 03/08/2026 | By News Bureau

Novartis Wins Health Canada Approval for RHAPSIDO in CSU

Novartis has received Health Canada approval for RHAPSIDO (remibrutinib), a new oral treatment for adults with Chronic Spontaneous Urticari (CSU).

Novartis | 29/07/2026 | By News Bureau |  131

Novartis Secures European Commission Approval for Itvisma in SMA

The European Commission (EC) has approved Novartis' Itvisma, the first gene replacement therapy in the European Union (EU) for a broad population with spinal muscular atrophy (SMA), including children, adolescents, and adults.

Novartis | 03/07/2026 | By News Bureau

Del-Brax from Novartis Achieves Primary Biomarker Endpoint in FSHD Study

Novartis reported positive phase 1/2 FORTITUDE study results for delpacibart braxlosiran (del-brax) in FSHD, meeting primary and key secondary biomarker endpoints. The therapy could become the first disease-modifying treatment for FSHD, with a phase 3 trial underway.

Novartis | 12/06/2026 | By News Bureau |  144

Novartis Reports Strong Long-Term Efficacy of Scemblix in Chronic Myeloid Leukemia Trial

Novartis’ Scemblix demonstrated sustained efficacy and a favourable safety profile over nearly three years of follow-up, reinforcing its potential as a frontline treatment option for adults with Philadelphia chromosome-positive chronic myeloid leukemia.

Novartis | 03/06/2026 | By News Bureau |  123

Novartis Expands US Manufacturing and R&D with Seventh Facility

Novartis advances its US expansion plan with a seventh facility, including a new API site in North Carolina to enable end-to-end manufacturing and accelerate delivery of innovative medicines.

Novartis | 04/05/2026 | By News Bureau |  167

Novartis Secures EC Approval for First Oral Targeted CSU Drug Rhapsido

Novartis introduces Rhapsido in Europe, offering a first-of-its-kind oral targeted therapy for patients with chronic spontaneous urticaria.

Novartis | 28/04/2026 | By News Bureau |  200